Microvascular and Fibrosis Imaging Study

Sponsor
Duke University (Other)
Overall Status
Completed
CT.gov ID
NCT01758250
Collaborator
(none)
63
1
60
1.1

Study Details

Study Description

Brief Summary

In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical Coherence Tomography (OCT) will be used to assess differences in microvascular function and density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous involvement: systemic sclerosis (SSc), morphea, dermatomyositis, cutaneous lupus and vasculitis, 2) sickle cell disease (SCD) and 3) chronic graft-versus-host disease (GVHD) compared to healthy subjects. The microvascular changes will be compared to overall treatment response in patients with scleroderma and chronic GVHD as assessments will be made before and after the patients start treatment for their diseases and determine if these imaging techniques provide valuable and reproducible data when assessing a patient's response to treatment for those diseases. In addition, the application of Acoustic Radiation Force Impulse (ARFI) in determining cutaneous thickness in patients with SSc, GVHD and morphea will be evaluated.

The investigators hypothesize that the vascular and dermal structures are altered in patients with autoimmune disease, SCD and chronic GVHD. In addition, they hypothesize that imaging modalities such as LDF, LDI, OCT, NVC, OPSI and ARFI can quantify such structural alterations and can be used to 1) detect early disease activity, 2) quantify and assess response to therapy and 3) quantify and correlate with overall disease activity.

Condition or Disease Intervention/Treatment Phase
  • Other: Acoustic Radiation Force Impulse (ARFI)
  • Other: Laser Doppler Flowmetry (LDF)
  • Other: Laser Doppler Perfusion Imaging (LDI)
  • Other: Optical Coherence Tomography (OCT)
  • Other: Orthogonal Polarization Spectral Imaging (OPSI)
  • Other: Nail fold video capillaroscopy (NVC)

Study Design

Study Type:
Observational
Actual Enrollment :
63 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects
Actual Study Start Date :
Feb 1, 2013
Actual Primary Completion Date :
Feb 1, 2018
Actual Study Completion Date :
Feb 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Systemic Sclerosis

Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

GVHD

Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

Undergoing HSCT

Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

Controls

Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

Sickle cell disease

Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

Cutaneous fibrosing disorder

Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.

Other: Acoustic Radiation Force Impulse (ARFI)

Other: Laser Doppler Flowmetry (LDF)

Other: Laser Doppler Perfusion Imaging (LDI)

Other: Optical Coherence Tomography (OCT)

Other: Orthogonal Polarization Spectral Imaging (OPSI)

Other: Nail fold video capillaroscopy (NVC)

Outcome Measures

Primary Outcome Measures

  1. Microvascular density in oral mucosa and skin [over 24 months]

    Microvascular density as evaluated using LDF, LDI, OPSI, OCT, NVC and AFRI, will be compared between subjects with and without disease.

  2. Microvascular Perfusion in oral mucosa and skin [over 24 months]

    Microvascular perfusion as evaluated using LDF, LDI, OPSI, OCT, NVC, and AFRI, will be compared between subjects with and without disease.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects above the age of 18 who are capable of giving informed consent with one of the following conditions: Scleroderma, Graft vs Host Disease, Sickle Cell Disease, Morphea, Connective Tissue Disease with cutaneous manifestations: cutaneous lupus, dermatomyositis, vasculitis, patients who are undergoing HSCT, or patients with a diagnosis of hematologic and non-hematologic malignancies without GVHD

  • Control patients include normal healthy controls above the age of 18 who are capable of giving informed consent.

Exclusion Criteria:
  • Patients who experience discomfort, will be prone to experience discomfort or cannot tolerate the position required for the imaging studies.

  • Subjects unable to provide informed consent.

  • Smokers, patients unable to tolerate caffeine avoidance for the day of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke University Medical Center Durham North Carolina United States 27710

Sponsors and Collaborators

  • Duke University

Investigators

  • Principal Investigator: Keith Sullivan, MD, Duke University
  • Principal Investigator: Adela Cardones, MD, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT01758250
Other Study ID Numbers:
  • Pro00039256
First Posted:
Jan 1, 2013
Last Update Posted:
Sep 11, 2020
Last Verified:
May 1, 2020

Study Results

No Results Posted as of Sep 11, 2020